⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602238 | 0.79 | — | — | |
| SCHEMBL3132845 | 0.72 | TSHR (0.30) | — | |
| SCHEMBL19857241 | 0.72 | CA2 (0.30) | — | |
| SCHEMBL18641300 | 0.71 | — | — | |
| SCHEMBL1660641 | 0.69 | — | — | |
| SCHEMBL1542549 | 0.69 | — | — | |
| SCHEMBL916367 | 0.64 | — | — | |
| SCHEMBL6130434 | 0.63 | — | — | |
| SCHEMBL18666201 | 0.63 | — | — | |
| SCHEMBL1470791 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024131893-A1 | IRE1α SMALL MOLECULE INHIBITORS | SHANGHAI YI ZHONG XING BIOTECHNOLOGY CO., LTD. (CN) | 2024-06-27 | — | — | WO | disclosed |
| CN-116836171-B | Sulfonamide compound and application thereof | 凌科药业(杭州)有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-113396150-B | Tricyclic JANUS kinase 1 inhibitors and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-116874440-A | Synthesis and application of isoxazoline-containing derivative | 贵州大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-116836171-A | Sulfonamide compound and application thereof | 凌科药业(杭州)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116710429-A | IRE1 alpha inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-09-05 | — | — | CN | disclosed |
| CN-116583276-A | IRE1 alpha inhibitors and uses thereof | 加利福尼亚大学董事会 | 2023-08-11 | — | — | CN | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116348455-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116102537-A | Quinolinone derivative and preparation method and application thereof | 四川大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-101641348-B | Imidazolidinone derivatives | HOFFMANN LA ROCHE | 2014-09-10 | — | — | CN | disclosed |
| CN-102317282-A | Hetero ring derivative | ASTELLAS PHARMA INC | 2012-01-11 | — | — | CN | disclosed |
| CN-1918129-B | Therapeutic agents | ASTRAZENECA AB | 2011-06-15 | — | — | CN | disclosed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | disclosed |
| CN-101277957-A | Preparation and use of tetrahydropyrrolo [3, 2-c] pyridin-4-one derivatives for treatment of obesity, psychiatric and neurological disorders | ASTRAZENECA AB (SE) | 2008-10-01 | — | — | CN | disclosed |
| CN-101223159-A | Pyrazole derivatives as CBI modulators | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | CN | disclosed |
| EP-1940820-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| CN-1964948-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2007-05-16 | — | — | CN | disclosed |
| WO-2007031721-A1 | MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| CN-1918129-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |